# AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
Canonical URL: https://biopharmsignal.com/news/ANTX/an2-therapeutics-announces-plans-to-advance-oral-epetraborole-into-phase-2-study-for-polycythemia-vera-pv
Ticker: ANTX
Company: AN2 Therapeutics
Source: AN2 Therapeutics
Published: 2026-03-03 21:00 EST
Original Source URL: https://investor.an2therapeutics.com
## Summary

Substantial clinical evidence provides rationale to initiate Phase 2 study in PV Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET / 6:30am PT MENLO PARK, Calif.

## Article Body
Substantial clinical evidence provides rationale to initiate Phase 2 study in PV Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET / 6:30am PT MENLO PARK, Calif.
## Recent Company News
- 2026-06-04 11:00 EST — [AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-positive-enabling-data-supporting-advancement-of-oral-an2-502998-to-phase-2-study-for-chronic-chagas-disease) — Source: AN2 Therapeutics
- 2026-05-21 11:00 EST — [AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-present-at-2026-jefferies-global-healthcare-conference) — Source: AN2 Therapeutics
- 2026-05-11 20:01 EST — [AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-and-scientific-highlights) — Source: AN2 Therapeutics
- 2026-05-07 20:01 EST — [AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum](https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum) — Source: AN2 Therapeutics
- 2026-03-31 11:00 EST — [AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease](https://biopharmsignal.com/news/ANTX/an2-therapeutics-announces-initiation-of-phase-2-investigator-initiated-clinical-trial-of-epetraborole-for-mycobacterium-abscessus-complex-lung-disease) — Source: AN2 Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)